INTRODUCTION
lung cancer, Lung cancer, death
LUNG CANCER, LUNG CANCER, STAGE II NSCLC
Lung cancer remains the primary cause of cancer‐related death globally.Criteria for clinical trial eligibility are often stringent and not reflective of real‐world patient cohorts, raising questions about the generalizability and appropriateness of using trial data in these settings. Studies examining real‐world patient cohorts with advanced lung cancer have shown that between 65% and 72% of patients are not eligible for clinical trials.We aimed to evaluate the proportion of stage III NSCLC patients eligible for durvalumab based on the PACIFIC trial at two Australian tertiary centers, the reasons for ineligibility, and assess the influence of eligibility and durvalumab use on patient outcomes to inform routine clinical practice.